Karin Rothgiesser

904 total citations
12 papers, 693 citations indexed

About

Karin Rothgiesser is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Karin Rothgiesser has authored 12 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Molecular Biology and 4 papers in Cancer Research. Recurrent topics in Karin Rothgiesser's work include HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (5 papers) and NF-κB Signaling Pathways (4 papers). Karin Rothgiesser is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (5 papers) and NF-κB Signaling Pathways (4 papers). Karin Rothgiesser collaborates with scholars based in Switzerland, Germany and Hungary. Karin Rothgiesser's co-authors include Michael O. Hottiger, Bernhard Lüscher, Süheda Erener, Monika Fey, Janin Hofmann, Burkhard Becher, Christine Lohmann, Christian M. Matter, Christian Besler and Sokrates Stein and has published in prestigious journals such as Nucleic Acids Research, SHILAP Revista de lepidopterología and Journal of Molecular Biology.

In The Last Decade

Karin Rothgiesser

12 papers receiving 688 citations

Peers

Karin Rothgiesser
Theresa Gorski Germany
Sita Kugel United States
Weinong Han United States
Prabhakaran Vasudevan United States
Anya Alayev United States
Luisa Tasselli United States
Kathryn J. Huber-Keener United States
Jingjie Yi United States
Melroy Miranda Switzerland
Debora Soncini Italy
Theresa Gorski Germany
Karin Rothgiesser
Citations per year, relative to Karin Rothgiesser Karin Rothgiesser (= 1×) peers Theresa Gorski

Countries citing papers authored by Karin Rothgiesser

Since Specialization
Citations

This map shows the geographic impact of Karin Rothgiesser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Rothgiesser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Rothgiesser more than expected).

Fields of papers citing papers by Karin Rothgiesser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Rothgiesser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Rothgiesser. The network helps show where Karin Rothgiesser may publish in the future.

Co-authorship network of co-authors of Karin Rothgiesser

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Rothgiesser. A scholar is included among the top collaborators of Karin Rothgiesser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Rothgiesser. Karin Rothgiesser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Güller, Ulrich, Stefanie Hayoz, Daniel Horber, et al.. (2025). Adjuvant Aspirin Treatment in PIK3CA -Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial. Clinical Cancer Research. 31(15). 3142–3149. 1 indexed citations
2.
Rothgiesser, Karin, W. Schönfeld, Roger von Moos, et al.. (2025). Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer. Clinical Breast Cancer. 25(6). 583–588. 1 indexed citations
3.
Güller, Ulrich, Stefanie Hayoz, Daniel Horber, et al.. (2024). 512O Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients: The phase III, prospective-randomized placebo-controlled multicenter SAKK 41/13 trial. Annals of Oncology. 35. S432–S432. 5 indexed citations
4.
Rothgiesser, Karin, Qiyu Li, Hanne Hawle, et al.. (2022). SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients. SHILAP Revista de lepidopterología. 2(1). 9–18. 1 indexed citations
5.
Eppenberger‐Castori, Serenella, Dirk Klingbiel, Thomas Ruhstaller, et al.. (2020). Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99. BMC Cancer. 20(1). 114–114. 7 indexed citations
6.
7.
Zweifel, Martin, Beat Thürlimann, Patrik Weder, et al.. (2017). Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. Endocrine Connections. 6(7). 549–556. 12 indexed citations
8.
Stein, Sokrates, Christine Lohmann, Nicola Schäfer, et al.. (2010). SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. European Heart Journal. 31(18). 2301–2309. 186 indexed citations
9.
Rothgiesser, Karin, Monika Fey, & Michael O. Hottiger. (2010). Acetylation of p65 at lysine 314 is important for late NF-κB-dependent gene expression. BMC Genomics. 11(1). 22–22. 70 indexed citations
10.
Rothgiesser, Karin, et al.. (2010). SIRT2 regulates NF-κB-dependent gene expression through deacetylation of p65 Lys310. Journal of Cell Science. 123(24). 4251–4258. 297 indexed citations
11.
Jayne, Sandrine, Karin Rothgiesser, & Michael O. Hottiger. (2009). CARM1 but not Its Enzymatic Activity Is Required for Transcriptional Coactivation of NF-κB-Dependent Gene Expression. Journal of Molecular Biology. 394(3). 485–495. 25 indexed citations
12.
Buerki, Christine, Karin Rothgiesser, Taras Valovka, et al.. (2008). Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA/p65. Nucleic Acids Research. 36(5). 1665–1680. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Theresa Gorski Breakdown of academic impact, for papers by Sita Kugel Breakdown of academic impact, for papers by Weinong Han Breakdown of academic impact, for papers by Prabhakaran Vasudevan Breakdown of academic impact, for papers by Anya Alayev Breakdown of academic impact, for papers by Luisa Tasselli Breakdown of academic impact, for papers by Kathryn J. Huber-Keener Breakdown of academic impact, for papers by Jingjie Yi Breakdown of academic impact, for papers by Melroy Miranda Breakdown of academic impact, for papers by Debora Soncini
Rankless by CCL
2026